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a b s t r a c t
The free fatty acid receptor 1 (GPR40/FFAR1) is a G protein-coupled receptor, which is activated by long
chain fatty acids. We have previously demonstrated that activation of brain GPR40/FFAR1 exerts an
antinociceptive effect that is mediated by the modulation of the descending pain control system.
However, it is unclear whether brain GPR40/FFAR1 contributes to emotional function. In this study, we
investigated the involvement of GPR40/FFAR1 in emotional behavior using GPR40/FFAR1 deﬁcient
(knockout, KO) mice. The emotional behavior in wild and KO male mice was evaluated at 9e10 weeks of
age by the elevated plus-maze test, open ﬁeld test, social interaction test, and sucrose preference test.
Brain monoamines levels were measured using LCeMS/MS. The elevated plus-maze test and open ﬁeld
tests revealed that the KO mice reduced anxiety-like behavior. There were no differences in locomotor
activity or social behavior between the wild and KO mice. In the sucrose preference test, the KO mice
showed reduction in sucrose preference and intake. The level of noradrenaline was higher in the hip-
pocampus, medulla oblongata, hypothalamus and midbrain of KO mice. Therefore, these results suggest
that brain GPR40/FFAR1 is associated with anxiety- and depression-related behavior regulated by the
increment of noradrenaline in the brain.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
The brain contains abundant fatty acids, which serve as con-
stituents of membranes and as an energy source. In addition, fatty
acids and their metabolites contribute to signal transduction be-
tween neurons or neurons and glial cells, suggesting that fatty acids
play a crucial role in development and functional maintenance in
the central nervous system (1). It is well known that
polyunsaturated fatty acids (PUFA), including arachidonic acid
(ARA; 20:4 u-6) and docosahexaenoic acid (DHA; 22:6 u-3), are
associated with cognitive and emotional function in healthy or
pathological conditions (2,3). For instance, the nutritional deﬁ-
ciency of these fatty acids of rodents causes decrease in learning
performance and vulnerability to stress which is susceptible to the
development of emotional dysfunction (4). Similarly, alterations in
PUFA levels in the plasma and brain are observed in subjects with
neuropsychiatric disorders (5). However, although fatty acids have
become increasingly important for the modulation of neuronal
function in the brain, the molecular mechanisms remain unknown.
The free fatty acid receptor 1 (GPR40/FFAR1) is a G protein-
coupled receptor, which is activated by long chain fatty acids,
such as ARA and DHA (6,7). Accumulating evidence has demon-
strated that GPR40/FFAR1 plays a crucial role in the regulation of
glucose homeostasis mediated by the free fatty acid-induced
Abbreviations: ARA, arachidonic acid; DHA, docosahexaenoic acid; GPR40/
FFAR1, free fatty acid receptor 1; EPM, elevated plus-maze test; PUFA, poly-
unsaturated fatty acid; EPM, elevated plus-maze test; OF, open ﬁeld; SI, social
isolation.
* Corresponding author. Fax: þ81 78 974 4780.
E-mail address: stoku@pharm.kobegakuin.ac.jp (S. Tokuyama).
Peer review under responsibility of Japanese Pharmacological Society.
Contents lists available at ScienceDirect
Journal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphs
http://dx.doi.org/10.1016/j.jphs.2016.09.007
1347-8613/© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Journal of Pharmacological Sciences 132 (2016) 249e254
potentiation of insulin secretion (8). In addition to the regulation of
endocrine function, GPR40/FFAR1 is involved in bone remodeling,
taste preference for fatty acids, and inﬂammation (9e11). These
ﬁndings suggest that free fatty acids exert their physiological
functions by the activation of GPR40/FFAR1.
Recent studies have indicated that GPR40/FFAR1 contributes to
physiological function in the central nervous system. We have
previously demonstrated that activation of brain GPR40/FFAR1
exerts an antinociceptive effect mediated by the modulation of the
endogenous opioid system or monoamine system, which is known
as the descending pain control system (12,13). We found that
activation of GPR40/FFAR1 facilitates the release of endogenous
opioid peptides and activates noradrenergic and serotonergic
neurons in the brain. In addition to pain control, it is well known
that brain opioids and the monoamine system are associated with
the regulation of emotional behavior (14,15). Moreover, it has been
reported that brain GPR40/FFAR1 signaling is associated with post-
ischemic hippocampal neurogenesis in primates (16). Similarly,
Zamarbide et al. reported that GPR40/FFAR1 is expressed in the
hippocampus and cortex of mice (17). Therefore, it is possible that
brain GPR40/FFAR1 signaling regulates emotional and cognitive
function. Previously, we found that repeated activation of brain
GPR40/FFAR1 decreases immobility behavior in the forced swim
test (18), although the involvement of brain GPR40/FFAR1 in
emotional behavior remains unclear.
In this study, we analyzed the emotional behavior of GPR40/
FFAR1 deﬁcient male mice (GPR40/FFAR1 KO mice) using the
elevated plus-maze test (EPM), open ﬁeld test, social interaction
test, and sucrose preference test. Moreover, we evaluated the brain
monoamine levels to clarify the relationship between abnormal
behavior and molecular change in GPR40/FFAR1 KO mice.
2. Materials and methods
2.1. Animals
Adult C57BL/6J male mice (7e8 weeks old) were obtained from
SLC (Hamamatsu, Japan). GPR40/FFAR1 KOmice were generated by
homologous recombination. Exon 1 of the Ffar1 gene was replaced
with a PGK-neo cassette. Frozen Ffar1/ fertilized oocytes were
inoculated into pseudopregnant fostermothers (ICR). GPR40/FFAR1
KO mice were maintained by crossbreeding homozygous mice. All
mice were housed 2e5 per cage with the same sex under standard
conditions [23e24 C, 12 h light/dark cycle (lights on from 8 a.m. to
8 p.m.)]. Food and water were available ad libitum. This study was
conducted in accordance with the Guiding Principles for the Care
and Use of Laboratory Animals adopted by the Japanese Pharma-
cological Society. The Ethical Committee for Animal Experimenta-
tion of Kobe Gakuin University approved all experiments (approval
number: A16-23; Kobe, Japan).
2.2. Experimental design
Fig. 1 shows the experimental design for the behavioral test. The
emotional behavior in wild and GPR40/FFAR1 KO mice was
evaluated using EPM, open ﬁeld, social interaction, and sucrose
preference tests at 9e10 weeks of age. All experimental mice were
subjected to all the behavioral tests according to the schedule
shown in Fig. 1. Each behavioral test was performed as one test per
day. After the social interaction test, mice were habituated in two
bottle conditions. The behavioral tests were performed during the
light phase. Data collection was blinded to the genotype condition.
2.3. EPM test
The EPM test was performed as previously described (19). The
plus-maze consisted of two open arms and two enclosed arms
(both 25 cm in length and 8 cm in width). The arms extended from
a central platform (8 cm in length and 8 cm inwidth). Themazewas
elevated 50 cm above the ﬂoor. The illumination levels on the open
and enclosed arms were similar (approximately 60 lux). Mice were
placed on the elevated plus-maze for 5 min and their behavior was
observed using a web camera. The total number of entries was
calculated as the number of entries into the four arms. The entries
into open arms were quantiﬁed as a percentage of the number of
entries into open arms to the total number of entries into four arms.
The time spent in open arms was quantiﬁed as a percentage of the
time spent in all four arms.
2.4. Open ﬁeld test
Mice were placed in a gray open ﬁeld (45  45 cm) surrounded
by a 35 cm high wall for 5 min. The camera was positioned 100 cm
above the center of the open ﬁeld. The illumination level on the
open ﬁeld was approximately 6 lux. The total travel distance and
time spent in the total area and a delineated center zone
(27  27 cm) were assessed using a video tracking system (ANY-
maze, Neuroscience Inc., Tokyo, Japan). The time spent in the
central zone was quantiﬁed as a percentage of the time spent in the
total area.
2.5. Social interaction test
The social interaction test was performed as previously
described (19). Experimental mice were placed in the open ﬁeld
(45  45 cm) for 2.5 min with an empty perforated plastic box
(8 8 cm) located at one end in the absence of unfamiliar wildmale
mice (no target session). The illumination level on the open ﬁeld
was approximately 60 lux. After the no target session, experimental
mice were returned to their home cage, and unfamiliar mice were
placed in the perforated plastic box. Experimental mice were
placed in the open ﬁeld for 2.5 min in the presence of unfamiliar
mice (target session). After the target session, experimental and
unfamiliar mice were returned to their home cages. The time spent
in the interaction zone surrounding the plastic box was measured
during both the no target and target sessions. Social interaction
behavior was assessed using a video tracking system (ANY-maze,
Neuroscience Inc., Tokyo, Japan), and was quantiﬁed as the time
spent in the interaction zone in both the no target and target phases
and as a ratio of the time spent in the interaction zone in the target
Fig. 1. Experimental schedule. EPM, elevated plus-maze test; OF, open ﬁeld test; SI, social interaction test; SP, sucrose preference test.
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phase divided by the time spent in the interaction zone in the no
target phase.
2.6. Sucrose preference
The sucrose preference test was performed as previously
described (19). Bottles (230mL)with stoppers ﬁttedwith ball-point
sipper tubes were ﬁlled with a 1% sucrose solution or tap water.
First, mice were habituated to drinking from two bottles of tap
water for 2 days. Next, they were given a free choice of 1% sucrose
solution or tap water. The positions of the two bottles were
switched every 24 h, and the sucrose and tap water intakes were
assessed once per day and estimated by weighing the bottles. The
sucrose preference was calculated as a percentage of total liquid
intake and was averaged over 3 days of testing.
2.7. LCeMS/MS analysis of monoamines in the each brain area of
the mouse
The LCeMS/MS analysis of monoamines in the mouse hippo-
campus, medulla oblongata, midbrain and hypothalamus was
performed as previously described (13). The hippocampal mono-
amines were extracted using a Monospin PBA column (GL Sciences
Inc., Tokyo, Japan). Each level of hippocampal monoamine was
corrected for the tissue weight and for isoproterenol level (Tokyo
Chemical Industry, Tokyo, Japan), which was used as the internal
standard. The results were expressed as the percentage of the
content of wild mice.
2.8. Statistical analysis
All data are expressed as mean ± standard error of the mean
(SEM). Signiﬁcant differences were determined by a two-tailed
Student's t-test (for two-group comparisons). The time spent in
the interaction zone in the social interaction test was assessed
using two-way repeated-measures ANOVA followed by Bonferro-
ni's post hoc test. Values of P < 0.05 were regarded as signiﬁcant.
3. Results
3.1. GPR40/FFAR1 KO mice showed anti-anxiety-like behavior in the
EPM test
The total number of entries into four arms was comparable
between wild (15.0 ± 1.2 counts) and GPR40/FFAR1 KO (13.2 ± 1.6
counts) mice (Fig. 2A). The number of entries into open arms (%)
was signiﬁcantly increased in GPR40/FFAR1 KO (40.2 ± 3.9%) mice
compared with wild (14.8 ± 3.1%) mice (Fig. 2B, P < 0.01). Moreover,
GPR40/FFAR1 KO mice spent a longer time in open arms than wild
mice (wild; 6.4 ± 1.7%, KO; 17.0 ± 3.4%, Fig. 2C, P < 0.05).
3.2. GPR40/FFAR1 KO mice showed normal locomotor activity and
anti-anxiety-like behavior in the open ﬁeld test
For total distance, there was no signiﬁcant difference between
wild (24.7 ± 2.7 m) and GPR40/FFAR1 KO (21.4 ± 1.0 m) mice
(Fig. 3A). GPR40/FFAR1 KO (15.8 ± 1.2%) mice spent more time in
the central zone compared with wild (10.0 ± 1.9%) mice (Fig. 3B).
3.3. GPR40/FFAR1 KO mice showed normal social behavior in the
social interaction test
GPR40/FFAR1 KO mice did not show abnormal locomotor ac-
tivity during the no target and target sessions (wild: no target
11.0 ± 1.1 m, target 7.4 ± 0.7 m; KO: no target 11.8 ± 1.2 m, target
7.2 ± 0.8 m; Fig. 4A). In the social interaction test, the time spent in
the interaction zone signiﬁcantly increased in the target session in
both wild and GPR40/FFAR1 KO mice [Fig. 2D; time effect:
F(1,16)¼ 34.23; P < 0.01], whereas there was no signiﬁcant effect of
genotype [genotype effect: F(1,16) ¼ 0.1382, P > 0.05]. In the social
interaction ratio, there was no signiﬁcant difference between wild
(251.0 ± 37.0%) and GPR40/FFAR1 KO (319.2 ± 96.0%) mice (Fig. 4C).
3.4. GPR40/FFAR1 KO mice showed reduction in sucrose preference
and intake in the sucrose preference test
The preference for sucrose was signiﬁcantly decreased in GPR40/
FFAR1 KO (85.2 ± 1.2%) mice compared with wild (88.9 ± 1.1%) mice
(Fig. 5A, P < 0.05). The total intake of water and sucrose was
signiﬁcantly decreased in GPR40/FFAR1 KO (3.7 ± 0.1 mL) mice
compared with wild (4.4 ± 0.1 mL) mice (Fig. 5B, P < 0.01). Although
the intake of water was comparable between wild (0.48 ± 0.04 mL)
and GPR40/FFAR1 KO (0.55 ± 0.04 mL) mice, GPR40/FFAR1 KO mice
showed a decreased intake of sucrose (wild; 3.9 ± 0.2 mL, KO;
3.2 ± 0.1 mL, Fig. 5C and D, P < 0.01). Moreover, the ratio of sucrose
intake divided by weight was signiﬁcantly decreased in GPR40/
FFAR1 KO (0.135 ± 0.004 mL/g body weight) mice compared with
wild (0.169 ± 0.006 mL/g body weight) mice (Fig. 5E).
3.5. GPR40/FFAR1 KO mice had higher noradrenaline levels in the
each brain area
The level of noradrenaline, but not serotonin and dopamine, was
signiﬁcantly increased in the hippocampus, medulla oblongata,
midbrain and hypothalamus of GPR40/FFAR1 KO mice compared
Fig. 2. Effect of GPR40/FFAR1 deﬁciency on anxiety-like behavior in the elevated plus-
maze test. (A) Total entries (B) Number of entries into open arms. (C) The time spent in
open arms. Data are expressed as mean ± SEM. Wild mice: n ¼ 10; KO mice: n ¼ 9.
*P < 0.05, **P < 0.01 vs. wild. Student's t-test.
Fig. 3. Effect of GPR40/FFAR1 deﬁciency on locomotor activity and anxiety-like
behavior in the open ﬁeld test. (A) Total distance (m) for 5 min. (B) The time spent
in the central zone (%). Data are expressed as mean ± SEM. Wild mice: n ¼ 10; KO
mice: n ¼ 9.
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with wild mice (Fig. 6A, noradrenaline: wild 100.0 ± 6.4%, KO
148.6 ± 11.0%; Fig. 6B, noradrenaline: wild 100.0 ± 8.6%, KO
157.2 ± 14.0%; Fig. 6C, noradrenaline: wild 100.0 ± 10.9%, KO
162.4 ± 48.0%; Fig. 6D, noradrenaline: wild 100.0 ± 9.9%, KO
119.1 ± 14.2%). Each level of hippocampal serotonin and dopamine
was signiﬁcantly increased in GPR40/FFAR1 KO mice compared
with wild mice (Fig. 6A; 5-HT: wild 100.0 ± 8.6%, KO 157.2 ± 14.0%;
dopamine: wild 100.0 ± 4.7%, KO 223.7 ± 46.9%), but not medulla
oblongata, midbrain and hypothalamus region.
4. Discussion
In this study, to investigate the involvement of GPR40/FFAR1 in
emotional function, we evaluated the emotional-related behavior
of GPR40/FFAR1 KO male mice for the ﬁrst time. It has been re-
ported that GPR40/FFAR1 KO mice show loss of increased glucose-
stimulated insulin secretion induced by free fatty acids and reduced
bone density (8,20), indicating the possibility that non-emotional
components induced by the deﬁciency of GPR40/FFAR1 affect
emotional behavior. However, GPR40/FFAR1 KO mice showed
normal locomotor activity, which provided important information
about interpretation of the results of the behavioral testing.
Moreover, it has been reported that GPR40/FFAR1 KO mice show
normal regulation of energy balance and food intake (21,22).
Therefore, we speculated that the emotional behavior of GPR40/
FFAR1 KO mice was appropriately evaluated using behavioral test
without the inﬂuence of body activity and other non-emotional
factors. Moreover, these ﬁndings suggest that GPR40/FFAR1 is not
involved in the regulation of locomotor activity. However, we
cannot exclude the possibility that the sensory impairments (visual,
olfactory) could affect behavior of knockout animals in this study.
Both anxiety-like behavior and sucrose preference/intake were
reduced in GPR40/FFAR1 KO male mice, while social behavior was
normal inKOmice. Theseﬁndings indicate that brainGPR40/FFAR1 is
involved in the modulation of anxiety- and depression-like behavior
in rodents. Previous studies have demonstrated that emotional
behavior is regulated by fatty acids, which are the endogenous li-
gands that bind toGPR40/FFAR1(1,3). For instance, shortor long term
exposure to a high-fat diet containing higher levels of saturated fatty
acids leads to alteration of anxiety-like behavior, locomotor activity,
and social interaction (23,24). Similarly, dietary intake or deprivation
ofu-3PUFAaffects several emotional behaviors, suggesting that fatty
acids play a crucial role in the regulation of emotional function
(25,26). Accumulating evidences have demonstrated that GPR40/
FFAR1 has a role as a sensor in mediating the action evoked by fatty
acids. Therefore, these ﬁndings suggest that dietary fatty acid-
induced alteration of some emotional behaviors is mediated by the
modulation of GPR40/FFAR1 signaling in the brain. Furthermore,
endogenous ligands for GPR40/FFAR1, such as ARA and DHA, are
essential components that are associated with the development of
the central nervous system (27,28). Therefore, it is possible that
GPR40/FFAR1 deﬁciency affects the development of the central ner-
vous system and instinctive behavior.
In EPM and open ﬁeld tests, GPR40/FFAR1 KO mice showed
reduced anxiety-like behavior. It has been reported that fatty acids
can regulate anxiety-like behavior. For example, systemic admin-
istration of palmitic acid, which is a long chain saturated fatty acid,
has been shown to increase anxiety-like behavior (29), indicating
that increased levels of free fatty acid in the plasma cause an
anxiogenic effect by activation of GPR40/FFAR1 signaling in the
brain. Consistent with these ﬁndings, this study revealed that
deﬁciency of GPR40/FFAR1 signaling produces an anxiolytic effect.
It has been reported that mice deﬁcient in fatty acid binding protein
7 (FABP7), which belongs to a family of intracellular lipid binding
proteins, showed abnormal composition of brain fatty acid and
increased anxiety-like behavior (30), indicating that the develop-
ment of an anxiety disorder is associatedwith the abnormal state of
brain fatty acids. On the other hand, EPM was utilized to measure
impulsive-like behaviors based upon the percentage of time spent
in the open arms of the maze (31). GPR40/FFAR1 KO mice showed
the number of entries into open arms and spent a longer time in
open arms, indicating that GPR40/FFAR1 KO mice may promote
impulsivity-like behavior. Therefore, these ﬁndings, including our
results, suggest that the abnormal function of GPR40/FFAR1
signaling contributes to the pathological mechanism of anxiety or
impulsivity-like behavior.
Furthermore, we found that GPR40/FFAR1 KO mice show
reduced sucrose preference and intake. Generally, the sucrose
preference test is used to evaluate depression-like behavior, which
is characterized as anhedonia (32). We have previously demon-
strated that GPR40/FFAR1 is localized in the hypothalamic
proopiomelanocortin-expressing neurons and is involved in the
secretion of b-endorphin, which is one of the endogenous opioid
Fig. 4. Effect of GPR40/FFAR1 deﬁciency on social behavior in the social interaction
test. (A) The total distance (m) and (B) time spent in the interaction zone (sec) during
no target and target sessions. (C) The ratio of the interaction zone. Data are expressed
as mean ± SEM. Two-way analysis of variance followed by Bonferroni's post hoc test.
Wild mice: n ¼ 9; KO mice: n ¼ 9. **P < 0.01 vs. no target wild. ##P < 0.01 vs. no target
KO.
Fig. 5. Effect of GPR40/FFAR1 deﬁciency on sucrose preference and intake in the su-
crose preference test. (A) Preference for sucrose. (B) Total intake of water and sucrose.
(C) Water intake. (D) Sucrose intake. (E) Sucrose intake calculated per body weight.
Data are expressed as mean ± SEM. Wild mice: n ¼ 10; KO mice: n ¼ 9. *P < 0.05,
**P < 0.01 vs. wild. Student's t-test.
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peptides (33). It is well known that sucrose intake can release
opioids, including b-endorphin, and is suppressed by treatment
with opioid receptor antagonists (34,35). Therefore, these ﬁndings
suggest that the decreased sucrose intake in GPR40/FFAR1 KOmice
is associated with b-endorphin release. Because there is no study
suggesting that sucrose can activate GPR40/FFAR1 signaling, su-
crose intake may indirectly release b-endorphin, which is mediated
by brain GPR40/FFAR1 signaling.
Next, GPR40/FFAR1 KO mice had increased monoamine levels in
the hippocampus. Hippocampus is one of themost highly connected
regions of the brain and function as a brain integrator of emotion
and cognition (36). Femenía et al. showed that serotonergic,
noradrenergic and dopaminergic neuron project to hippocampus
area (37). It has been reported that GPR40/FFAR1 is widely
expressed in the brain of mice and GPR40/FFAR1 agonists activate
cultured neurons derived from the hippocampus and cortex (17). Of
all, hippocampal GPR40/FFAR1 signaling is associated with neuro-
genesis mediated by the cAMP response element-binding protein
(CREB) pathway, which is also regulated by brain-derived neuro-
trophic factor (BDNF) (38). Therefore, these ﬁndings suggest that the
hippocampus is a crucial brain region associated with the physio-
logical function of GPR40/FFAR1. The brainmonoamine systemplays
a central role in the regulation of emotional function. Previous
studies have demonstrated that anxiety-like behavior is regulated
by the hippocampal monoamine system (39e41). Furthermore, to
clarify whether other area of brain may affect by the deletion of
GPR40/FFAR1, we tested the changes of monoamine levels in other
brain region of GPR40/FFAR1 KOmice. We found that the increment
of noradrenaline level in the medulla oblongata, hypothalamus and
midbrain was observed in GPR40/FFAR1 KO mice compared to wild
mice, but not serotonin and dopamine. We have previously
demonstrated that GPR40/FFAR1 is expressed in noradrenergic
neurons, and activation of GPR40/FFAR1 increased c-fos, a neuronal
activation maker, expression in neurons (13), indicating that GPR40/
FFAR1 can regulate the function of noradrenergic and serotonergic
neurons. In addition, it has been reported that dietary deprivation of
u-3 PUFA impairs brain monoamine systems (42,43). In addition, it
is reported that anxiety disorder including post-traumatic stress
disorder (PTSD) (44,45) shows the abnormal noradrenergic system
in the brain, suggesting that the increment of noradrenaline in the
wide brain area may induce, at least in part, abnormal behavior in
GPR40/FFAR1 KO mice. Our ﬁndings suggest that GPR40/FFAR1
signaling may contribute to the regulation of monoaminergic sys-
tem in mice. Furthermore, it is thought that deletion of GPR40/
FFAR1 could be induced abnormal development of noradrenergic
neuron and might alter emotional behavior mediated by the
abnormal state of monoamine systems in the brain.
However, Gingrich and Hen reported that absence of the gene at
all stages of ontogenesis of mice may interfere with the normal
developmental program and/or the organismmay undergo changes
in other systems to compensate for gene absence (46). In addition,
potentially altered maternal behavior of GPR40/FFAR1 KO dams
might have a great impact on the resulting phenotype of adult KO
offspring because of signiﬁcant role of maternal behavior in the
expression of a phenotype change in adult mice (47,48). Therefore,
we cannot excluded that obtained behavioral and physiological
changes can be attributed to above-mentioned factors.
In conclusion, we found that GPR40/FFAR1 contributes to the
regulation of anxiety- and depression-related behavior in the
central nervous system. Moreover, deﬁciency of GPR40/FFAR1 in-
duces abnormalities in the monoamine system in the brain. These
ﬁndings suggest that brain GPR40/FFAR1 signaling is associated
with the pathology of neuropsychiatric disorders, including anxiety
disorders and depression.
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